Swiss drugmaker Roche Holding AG (ROG.VX) will have grown considerably faster than the market this year, the group's head was quoted as saying in an interview with Swiss newspaper SonntagsZeitung.
"2009 will be a very good year. Even without Tamiflu, we will significantly outpace the market. Thanks to the quality of our pipeline we will also be able to build up our market position in the long term," CEO Severin Schwan said.
Roche has 10 new investigational agents in late stage development, Schwan said.
Roche, the world's biggest maker of cancer drugs, posted a forecast-beating 10 percent rise in third-quarter sales in October, helped by demand for antiviral drug Tamiflu due to the H1N1 swine flu pandemic.[ID:nLD628052]
Tamiflu sales are likely to be above 2.7 billion Swiss francs ($2.59 billion) this year and Schwan said the group would likely see significant sales next year, but it was difficult to be more precise as it was not yet clear how swine flu and seasonal flu would develop.
"2009 will be a very good year. Even without Tamiflu, we will significantly outpace the market. Thanks to the quality of our pipeline we will also be able to build up our market position in the long term," CEO Severin Schwan said.
Roche has 10 new investigational agents in late stage development, Schwan said.
Roche, the world's biggest maker of cancer drugs, posted a forecast-beating 10 percent rise in third-quarter sales in October, helped by demand for antiviral drug Tamiflu due to the H1N1 swine flu pandemic.[ID:nLD628052]
Tamiflu sales are likely to be above 2.7 billion Swiss francs ($2.59 billion) this year and Schwan said the group would likely see significant sales next year, but it was difficult to be more precise as it was not yet clear how swine flu and seasonal flu would develop.
Posts
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.